Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker

Andreas Krieg1*, Sabrina Mersch1, Nadine Wolf2, Nikolas H Stockelein1, Pablo E Verde3, Jan Schulte am Esch 2nd1, Sebastian Heikaus2, Helmut E Gabbert2, Wolfram T Knoefel1 and Csaba Mahotka2*

Abstract

Background: TNF-related apoptosis inducing ligand (TRAIL) belongs to the TNF-superfamily that induces apoptotic cell death in a wide range of neoplastic cells in vivo as well as in vitro. We identified two alternative TRAIL-splice variants, i.e. TRAIL-β and TRAIL-γ that are characterized by the loss of their proapoptotic properties. Herein, we investigated the expression and the prognostic values of the TRAIL-splice variants in gastric carcinomas.

Methods: Real time PCR for amplification of the TRAIL-splice variants was performed in tumour tissue specimens and corresponding normal tissues of 41 consecutive patients with gastric carcinoma. Differences on mRNA-expression levels of the TRAIL-isoforms were compared to histo-pathological variables and correlated with survival data.

Results: All three TRAIL-splice variants could be detected in both non-malignant and malignant tissues, irrespective of their histological staging, grading or tumour types. However, TRAIL-β exhibited a higher expression in normal gastric tissue. The proapoptotic TRAIL-α expression was increased in gastric carcinomas when compared to TRAIL-β and TRAIL-γ. In addition, overexpression of TRAIL-γ was associated with a significant higher survival rate.

Conclusions: This is the first study that investigated the expression of TRAIL-splice variants in gastric carcinoma tissue samples. Thus, we provide first data that indicate a prognostic value for TRAIL-γ overexpression in this tumour entity.

Keywords: TRAIL, Alternative splicing, Apoptosis, Gastric carcinoma

Background

TRAIL/APO2L (tumour necrosis factor related apoptosis-inducing ligand) is classified accordingly to its membranous topology as type II transmembrane protein that was identified by two research groups as a member of the TNF superfamily [1,2]. Unlike other TNF family members, such as TNFα or CD95L/FasL, TRAIL was detected in numerous normal as well as malignant cells and tissues [1,2]. In addition, it has been shown that TRAIL triggered apoptotic cell death in cancer cells, while most normal cells remained unaffected [3-7]. Interestingly, treatment of tumour cells with recombinant TRAIL suppressed their growth in mice [8] and improved survival of tumour-bearing animals [3]. Thus, making the TRAIL-system a promising target for anticancer therapies, that are still under investigation in several clinical trials as reviewed by Dimberg and colleagues [9].

The identification of five receptors that are capable to bind TRAIL suggests that signal transduction mediated by TRAIL is more complex when compared to the signaling pathways of other TNF-family members [7,10-16].

Upon binding of TRAIL to the death domain containing receptors TRAIL-R1/DR4 and TRAIL-R2/DR5/KILLER/TRICK2, receptor homotrimerization is induced, leading to the formation of a so called death inducing signaling complex (DISC) which sets the apoptotic machinery in motion [5,6,15-21]. However, TRAIL-R3/DcR1/TRID, lacking a cytoplasmic domain and TRAIL-R4/DcR2/TRUNDD, exhibiting an incomplete death domain, protect cells from TRAIL-induced
cell death by direct antagonism [10,11,13-17,22]. Although with a low affinity, osteoprotegerin (OPG) has also been reported to bind TRAIL [12].

In addition to the apoptosis inducing signaling cascade, TRAIL can also activate pathways that promote survival and cell proliferation via the NF-κB, protein kinase B/Akt and MAP-Kinase pathways [10,23-27]. Thus, cells that are characterized by a death resistant phenotype when treated with TRAIL may convert into highly aggressive tumours that exhibit an increase in proliferation and metastatic capacity when stimulated with TRAIL [28,29]. Thereby, mechanisms promoting TRAIL resistance have been identified on different levels of the TRAIL pathway. These mechanisms include i.e. mutations of death receptors, overexpression of FLICE-like inhibitory protein, BcI2 family proteins or Inhibitor of apoptosis (IAP) proteins [9].

Recently, several studies have focused on the prognostic significance of the TRAIL-system in different types of cancer. Interestingly, TRAIL-positive tumours less frequently obtained a pathological complete response in cervical cancer [30]. Poorly differentiated areas in NSCLC showed a strong staining pattern for TRAIL [31] and in colorectal cancer an increased TRAIL expression within the tumour was associated with worse overall survival [32].

Alternative splicing is a posttranscriptional modification process that has been shown to be involved in the regulation of apoptosis by promoting the translation of multiple proteins from a single gene that results in a sometimes functionally heterogenic pool of proteins with antagonistic functions [33,34].

Recently, we were able to identify and characterize also alternative splice variants of genes that belong to the TRAIL-system [35,36]. Alternative splicing of the TRAIL pre-mRNA led to the synthesis of two isoforms that were designated TRAIL-β and TRAIL-γ [35]. Both TRAIL-β and TRAIL-γ exhibited structurally an extensive truncation of their N-terminal binding domain which functionally was associated with the inability of mediating any proapoptotic signal.

Although previously the expression levels of TRAIL were investigated in gastric carcinomas [37], to date there are no data available that analyzed the expression of the alternative TRAIL splice variants in malignant diseases such as gastric carcinomas (for better discrimination TRAIL is denoted in this article as TRAIL-α). Thus, in our study we focused now on the quantification of mRNA levels of TRAIL-α TRAIL-β and TRAIL-γ in gastric carcinomas and correlated these expression levels with clinico-pathological variables and survival data. Since there are currently no specific antibodies available that can distinguish between the different splice variants, we quantified their expression levels by performing a reverse transcriptase and polymerase chain reaction (RT–PCR).

Using this experimental approach our data suggest that alternative splicing of the TRAIL gene might be involved in the molecular pathology of gastric carcinomas.

**Methods**

**Patients and specimens**

Matched neoplastic and non-neoplastic tissue specimens were obtained from 41 consecutive patients who underwent subtotal or total gastrectomy because of gastric carcinomas between 1996 and 2000.

After surgical resection, specimens of gastric carcinomas and corresponding normal gastric tissue were excised by a pathologist and immediately snap frozen in liquid nitrogen and stored at −80°C until usage. Tumour samples were selectively taken from the macroscopically identified tumour centre and the content of at least 70% of tumour was verified by microscopy. Pathological review, tumour staging, grading and typing were performed according to the principles outlined by the WHO [38] and the UICC [39]. Clinico-pathological parameters such as age, sex, primary site of disease, *Helicobacter pylori* infection, lymphatic vessel invasion and blood vessel invasion were recorded. Ethics Committee of the Medical Faculty, University Dusseldorf approved the study protocol (Number 3821).

**RNA isolation**

Total RNA of tissue specimen were isolated by performing the acid guanidium thiocyanate phenol chloroform extraction with minor modifications as described previously [40]. The quality of total RNA was confirmed by integrity of the 28S and 18S ribosomal RNA in ethidium-bromide stained agarose gels.

**Reverse transcription and Semi-quantitative Polymerase chain reaction**

Reverse transcriptase reaction was performed in a final volume of 20 μl using 2 μg total RNA and a final concentration of 5 mM MgCl₂, 1 X reverse transcription buffer, 1 mM each dNTP, 20 U recombinant RNase inhibitor RNasin, 15 U AMV reverse transcriptase as well as 0.5 μg oligo(dT) primer (all Promega, Heidelberg, Germany). The samples were incubated at 42°C for 1 hour with a final denaturation at 94°C for 15 min.

The amplification of the TRAIL splice variants was performed on the LightCycler System (Roche Diagnostics, Mannheim, Germany) using the Platinum SYBR Green qPCR Super Mix-UDG kit (Invitrogen, Karlsruhe, Germany). Therefore, 4 μl of synthesized cDNA was amplified in a total volume of 20 μl containing 10 μl Platinum SYBR Green qPCR Super Mix-UDG which included the Taq DNA polymerase, SYBR Green I
fluorescent dye, reaction buffer, dNTPs and uracil DNA glycosylase (UDG), 1 μl BSA and 10 pmol of each TRAIL-α specific primer (forward primer, GTC AGC TCG TTA GAA AGA TGA T and reverse primer, GCT CAG GAA TGA ATG CCC AC), TRAIL-β specific primer (forward primer, ATG GCT ATG ATG GAG GTC CA and reverse primer, GCT TTT CTT TCT AAC GAG CTG A); TRAIL-γ specific primer (forward primer, ATG GCT ATG ATG GAG GTC CA and reverse primer, GCT TTT CTG CTT CAG CTC GT). In addition, the housekeeping gene GAPDH was amplified using specific primers (forward primer, ACG AGA ATT TGG TCG TAT TTG GCG and reverse primer, CTC CTG GAA GAT GGT GAT GG).

PCR assays were composed of an initial denaturation at 95°C for 5 min, followed by 50 cycles of 1 s denaturation at 95°C, 20 s annealing at 64°C, extension at 72°C for 20 s at a temperature transition rate of 20°C/s and a final extension at 72°C for 5 min. In every PCR the hot start was performed to prevent the formation of unspecific products and primer dimers. In addition to the melting curve analysis, specificity of the PCR was controlled by agarose gel electrophoresis and products were sequenced with gene specific oligonucleotides.

Quantification of TRAIL variants

The amount of TRAIL-α, TRAIL-β and TRAIL-γ transcripts was calculated semi-quantitatively in relation to the amount of the amplified housekeeping gene GAPDH serving as external standard. For the relative quantification, GAPDH specific PCR on cDNA standards comprising a fivefold dilution series on cDNA synthesized from HeLa cells was performed and used to create a standard curve by plotting the crossing point (CP) values against the dilution factor. Every dilution was run at least in duplicate. TRAIL-α, TRAIL-β, TRAIL-γ and GAPDH expression levels were normalised to the standard curve by GAPDH expression levels obtained from these cDNA standards which were amplified along the samples in every run. The number of gene copies was calculated by the LightCycler Software Version 3.5.3 according to the second derivative maximum method.

Statistical analysis

GAPDH expression values for each sample were used to normalise the respective amplification values of TRAIL transcript and to calculate the ratios of relative mRNA levels. Statistical analysis was performed using SPSS 12.01 statistical software package (SPSS Inc., Chicago, IL, USA) or Graph Pad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). To determine the differences of expression levels between the TRAIL splice variants in normal or neoplastic transformed gastric tissue statistical analyses were performed by using the Wilcoxon test.

| pTNM stage | UICC stage | No. of patients |
|------------|------------|-----------------|
| pT1        |            |                 |
| N0M0       | I A        | 3               |
| N1M0       | I B        | 1               |
| pT2        |            | 28              |
| N0M0       | I B        | 7               |
| N1M0       | II         | 13              |
| N2M0       | III A      | 5               |
| N3M0       | IV         | 3               |
| pT3        |            | 8               |
| N1M0       | III A      | 3               |
| N2M0       | III B      | 1               |
| N3M1       | IV         | 4               |
| pT4        |            | 1               |
| N1M0       | IV         | 1               |

Table 1 Distribution of tumour staging and typing of the 41 gastric carcinomas

Figure 1 Expression levels of TRAIL splice variants. Relative (GAPDH-normalized) mRNA levels of the different TRAIL variants in non-neoplastic and corresponding neoplastic gastric tissue specimen (N = 41). P-values were calculated by the Wilcoxon-test; sv = splice variant.
The differences in the expression levels of all TRAIL variants according to clinico-pathological parameters and between gastric carcinomas and normal gastric tissues were analyzed using the Mann–Whitney–U–test. One-way ANOVA and Bonferroni’s Multiple Comparison test was performed to compare expression levels of TRAIL splice variants with the primary site of gastric cancer. A two-tailed p-value less than 0.05 was considered to indicate statistical significance.

For survival analyses the median expression level was calculated and patients were categorized into two groups (≥ median and < median). Life table curves were estimated using the Kaplan-Meier analysis and the differences in survival were compared using the log-rank-test. A p-value less than 0.05 indicated statistical significance. Multiple proportional hazard Cox regression analysis was performed to investigate the prognostic value of TRAIL splice variants and clinico-pathological variables. The AIC (Akaike Information Criteria) was used for model selection.

Results
TRAIL splice variants are expressed in neoplastic and non-neoplastic gastric tissues
In this study we included patients that had undergone subtotal or total gastrectomy because of gastric carcinomas with UICC stages I-IV irrespectively of the tumour grading, histological type, margins of resection, age, sex or tumour localisation. Thus, we enrolled forty-one patients in this study comprising 27 male and 14 female patients with a median age of 64 ± 10.9 years (range 40–80 years). Samples included gastric carcinomas classified as UICC stage I (n = 11), stage II (n = 13), stage III (n = 9) and stage IV (n = 8) (Table 1). In seven patients margins of resection were tumour positive as diagnosed by histology and therefore being classified as R1 resection. Four patients showed at the time of diagnosis already distant metastases.

Irrespective of the histological type, grade and stage of the tumour, TRAIL-α, TRAIL-β and TRAIL-γ could be detected in all gastric carcinoma specimens and corresponding normal gastric tissue (Additional file 1: Figure S1). Specificity of amplification was revealed by gel electrophoresis which showed only a single amplification product (Additional file 1: Figure S1) as well as by melting curve analysis (Additional file 2: Figure S2). Whereas expression levels of the distinct TRAIL variants showed only minor differences in normal gastric tissues, TRAIL-α was the predominant transcript in gastric carcinomas (p < 0.001) (Figure 1).

Correlations between the expression levels of TRAIL splice variants and clinico-pathological parameters
To further evaluate whether expression patterns of the different TRAIL variants might correlate with histopathological variables such as tumour staging, grading, typing, blood vessel invasion, lymphatic vessel invasion or Helicobacter pylori infection and other clinical parameters we performed the Mann–Whitney–U–test for non-parametric data or one-way ANOVA and Bonferroni’s Multiple Comparison test to compare TRAIL expression with tumour location. As summarized in Table 2, this analysis did not provide any statistically significant correlation between the investigated clinico-pathological variables and the expression levels of wild type TRAIL-α or the alternative splice variants TRAIL-β and TRAIL-γ.

TRAIL-β is downregulated in gastric carcinomas
Recently, exclusively the expression of TRAIL without referring to its alternative splice variants has been

### Table 2 Correlation between expression levels of TRAIL variants and clinicopathological parameters

| Variables                  | No. of patients | TRAIL-α | TRAIL-β | TRAIL-γ | p-value |
|----------------------------|----------------|---------|---------|---------|---------|
| Primary site               |                | 0.898   | 0.415   | 0.728   |         |
| Proximal                   | 16             | 0.898   | 0.415   | 0.728   |         |
| Corpus/Fundus              | 13             | 0.898   | 0.415   | 0.728   |         |
| Antrum/Pylorus             | 12             | 0.898   | 0.415   | 0.728   |         |
| Stage (UICC)               |                | 0.682   | 0.588   | 0.721   |         |
| I + II                     | 17             | 0.682   | 0.588   | 0.721   |         |
| III + IV                   |                | 0.682   | 0.588   | 0.721   |         |
| Histological gradea       |                | 0.625   | 0.582   | 0.494   |         |
| G2                         | 9              | 0.625   | 0.582   | 0.494   |         |
| G3                         | 31             | 0.625   | 0.582   | 0.494   |         |
| Histological type          |                | 0.089   | 0.272   | 0.231   |         |
| Intestinal                 | 17             | 0.089   | 0.272   | 0.231   |         |
| Diffuse                    | 21             | 0.089   | 0.272   | 0.231   |         |
| Mixed                      | b              | 0.089   | 0.272   | 0.231   |         |
| Lymphatic vessel invasion  |                | 0.948   | 0.509   | 0.895   |         |
| Positive                   | 23             | 0.948   | 0.509   | 0.895   |         |
| Negative                   | 18             | 0.948   | 0.509   | 0.895   |         |
| Blood vessel invasion      |                | 0.349   | 0.633   | 0.681   |         |
| Positive                   | 8              | 0.349   | 0.633   | 0.681   |         |
| Negative                   | 33             | 0.349   | 0.633   | 0.681   |         |
| Helicobacter pylori infection |           | 0.234   | 0.127   | 0.071   |         |
| Positive                   | 13             | 0.234   | 0.127   | 0.071   |         |
| Negative                   | 28             | 0.234   | 0.127   | 0.071   |         |
| Sex                        |                | 0.945   | 0.290   | 0.858   |         |
| female                     | 14             | 0.945   | 0.290   | 0.858   |         |
| male                       | 27             | 0.945   | 0.290   | 0.858   |         |
| Age                        |                | 0.764   | 0.140   | 0.969   |         |
| < 64 Jahre                 | 19             | 0.764   | 0.140   | 0.969   |         |
| ≥ 64 Jahre                 | 22             | 0.764   | 0.140   | 0.969   |         |

*G1 (n=0) and G4 (n=1) not included due to the low case number.

bNot included in statistical analysis due to the low case number.
analyzed in primary and metastatic gastric carcinomas. Therefore, we analyzed the expression of the different TRAIL splice variants by comparing matched neoplastic and non-neoplastic tissue samples. Whereas the expression levels of TRAIL-α and -γ showed no significant difference when comparing gastric carcinomas with the corresponding normal gastric tissue, TRAIL-β expression was significantly decreased in gastric carcinomas (p = 0.001) (Figure 2).

Previously we reported that TRAIL-β and TRAIL-γ are characterized by the loss of their proapoptotic function. Thus, a reduced production of the non-proapoptotic isoforms by alternative splicing might result in an accumulation of proapoptotic TRAIL-α mRNAs. Therefore, we compared the mRNA expression levels of proapoptotic TRAIL-α with those of non-proapoptotic TRAIL-β and -γ in non-neoplastic as well as neoplastic tissues by calculating the ratio between mRNA levels of proapoptotic TRAIL-α on one site and non-proapoptotic TRAIL-β plus TRAIL-γ on the other site. Interestingly, this ratio revealed a significant 2-fold increase of proapoptotic TRAIL-α in gastric carcinomas when compared to normal tissue specimens (Figure 3).
Prognostic value of non-proapoptotic TRAIL-γ mRNA

In order to determine a prognostic value of mRNA expression levels of TRAIL splice variants in gastric carcinomas we estimated survival curves according to Kaplan-Meier. To eliminate any bias on survival analyses, eight patients were excluded from survival analyses because of distant metastases (n = 4) and/or non-tumour free resection margins (n = 7). The median postoperative follow up of the remaining patients (n = 33) was 24 ± 51 months (range 1 – 148 months). Whereas no statistical difference in survival could be observed for the expression levels of TRAIL-α and -β (Figure 4A and B), high expression of non-proapoptotic TRAIL-γ variant (≥ median 0.088) was significantly (p = 0.02) associated with a better survival (TRAIL-γ high vs. TRAIL-γ low: 6.1 vs. 1.2 years) (Figure 4C).

To provide better estimates of survival probabilities we explored the impact of several variables on survival using two Cox regression models. Thus, the model with all possible interactions (model 1) such as the level of expression of TRAIL-α, -β or -γ (high vs. low), lymphatic vessel invasion, blood vessel invasion, histological type, age, lymph node metastases, UICC stage and sex showed an AIC value that was comparable to the AIC value of the best model (model 2) (Table 3). In addition, as the analysis of variance (ANOVA) revealed, interactions among these variables were not statistically significant (p = 0.51). We conclude empirically that the three variables: expression level of TRAIL-γ, age, and UICC stage were independent prognostic factors.

Discussion

In this study, we analyzed the expression levels and prognostic value of TRAIL splice variants in gastric carcinomas and compared the expression of these variants in neoplastic tissues with the mRNA levels in corresponding normal gastric tissues. In contrast to the work by Koyama et al. [37] that reported a TRAIL protein expression in 55.6 % of the cells from primary gastric carcinomas and 53.7 % of the cells from metastatic gastric carcinomas, respectively, we were able to detect TRAIL in all gastric carcinoma samples on mRNA levels. This difference might be explained by the use of the more sensitive PCR method in our study. However, our study demonstrates for the first time the expression of the previously identified TRAIL isoforms (i.e. TRAIL-β and -γ) on mRNA levels in neoplastic and non-neoplastic gastric tissue specimens.

Recently, TRAIL has attracted a lot of attention as TNF-superfamily member because it is capable to trigger apoptosis in neoplastic transformed cells, implicating its potential as promising agent in targeted therapies against cancer [3-9]. Although in some cases the combination with chemotherapeutic agents is necessary to overcome TRAIL-resistance, first clinical trials show antitumour activity only with mild side effects [9]. Aside of its antitumor effects, TRAIL can activate via NF-кB signaling pathways that promote survival by activation of protein kinase B/Akt and MAP-Kinases [10,23-27]. However, the diversity in controlling TRAIL actions has been extended by the molecular cloning of TRAIL-β and -γ
which are structurally characterized by an extensive deletion of their N-terminal binding domain that consequently results in a loss of function when overexpressed in mammalian cells [35]. Thus, these alternative splice variants may be involved in the fine-tuning of TRAIL actions by simply influencing the translation of the classical apoptosis inducing TRAIL-α variant. In this context, alternative splicing of pre-mRNA was found to play a functionally important role as regulatory mechanism for apoptosis by processing distinct mRNAs from a pre-mRNA that in turn results in the translation of a pool of protein isoforms exhibiting often antagonistic biological properties [33].

Herein, we show that TRAIL-α and its alternatively spliced non-apoptotic isoforms TRAIL-β and -γ were detectable on mRNA levels in matched pairs of normal and neoplastic gastric carcinoma tissue specimens from patients that underwent surgery because of gastric carcinoma. Moreover, these TRAIL-variants were expressed in all histological types of gastric carcinoma, irrespective of tumour grading and staging. Interestingly, proapoptotic TRAIL-α exhibited the highest expression among the TRAIL variants in neoplastic tissues, but not in normal tissue specimens. In addition, the comparison between normal and tumour tissue illustrated a significant decrease of TRAIL-β mRNA levels in gastric carcinomas. A first clue for a functional role of this tumour specific downregulation became evident when comparing the expression levels of the proapoptotic TRAIL-variant with the non-proapoptotic isoforms (TARIL-β and -γ), showing a tumour specific increase of proapoptotic TRAIL-α. Thus, the tumour specific downregulation of the TRAIL-β mRNA might affect the TRAIL-α functions by a regulation on mRNA levels. Since all TRAIL variants originate from a common pool of a precursor RNA, the process of alternative splicing could permit an increase of proapoptotic TRAIL-α mRNA if for example the spliceosome catalyzes less RNAs with excluded exons such as TRAIL-β and TRAIL-γ transcripts. As a consequence, this could result in an increase of translated TRAIL-α protein which could support tumour growth by two ways. First, a TRAIL-induced activation of NF-κB could mediate the transcription of antiapoptotic targets such as XIAP and cFLIP, protecting the tumour from proapoptotic stimuli and permitting proliferation and metastasis. In this context, it has been demonstrated that TRAIL supported the conversion into a highly metastatic phenotype in pancreatic carcinomas by the induction of proinflammatory cytokines [29]. On the other hand, as suggested by others, the overexpression of ligands of the TNF-family such as FasL and TRAIL may be associated with immunological advantages for tumour cells by counterattacking tumour infiltrating cytotoxic lymphocytes [41-43]. In this context, a decrease in the processing of non-proapoptotic TRAIL variants (i.e. TRAIL-β and TRAIL-γ) as we observed in gastric carcinomas could permit the increase of translated TRAIL-α which in turn could induce programmed cell death in tumour infiltrating immune cells and thus promoting the immune escape and tumour surveillance of gastric carcinomas. Since a decrease of synthesized TRAIL-γ transcripts could permit an increase of transcribed and finally translated proapoptotic TRAIL-α, this could also explain our observation that downregulation of TRAIL-γ was associated with a worse prognosis. Thus, we hypothesize that the biological property of non-proapoptotic TRAIL splice variants has to be more likely interpreted as result of competing for translation with proapoptotic TRAIL-α.

**Conclusion**

Taken together, our present study provides first evidence on the in vivo expression of TRAIL-splice variants in gastric carcinomas. The tumour-specific downregulation of TRAIL-β was associated with an increase of the proapoptotic TRAIL-α isoform in neoplastic tissues when compared to corresponding non-neoplastic tissue.
specimens. In addition, multivariate analyses identified TRAIL-γ as an independent prognostic marker. These data support the hypothesis that alternative splicing of TRAIL may play a crucial role in the tumour biology of gastric carcinomas.

**Additional file**

*Additional file 1: Figure S1.* Expression of TRAIL variants. RT-PCR analyses of TRAIL splice variants in gastric carcinoma (A-C) and normal gastric tissue (D-F) specimen by Real-Time-PCR (LightCycler) technology. SYBR Green I mediated fluorescence (y-axis) upon amplification was measured once per cycle (x-axil). TRAIL-α could be detected at cycles 24–28, whereas TRAIL-δ and TRAIL-γ were detectable at cycles 28–32. The specificity of amplification products by agarose gel electrophoresis is shown in the upper framed box.

*Additional file 2: Figure S2.* Melting curve analyses of amplified PCR products. Melting curve analyses from exemplary PCR experiments of A) TRAIL-α, B) TRAIL-β and C) TRAIL-γ from exemplary PCR experiments demonstrated that only one specific product was amplified.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

AK and CM designed and coordinated the study, interpreted the data and wrote the manuscript. AK, SM and NW performed and analyzed the Semi-quantitative Polymerase chain reaction. SH and NHS contributed substantially to the data acquisition and drafting the manuscript. PEV and NHS contributed to and supervised the statistical analysis. CM and SH were involved in the sample acquisition, sample selection, clinical data acquisition and preparing the manuscript. JSAE, HEG, and WTK contributed to the data acquisition and interpretation of the data and revised the manuscript critically. All authors read and approved the final version of the manuscript.

**Acknowledgements**

We thank Sigrid Khalil for technical assistance. This work was in part supported by the Deutsche Forschungsgemeinschaft (DFG).

**Author details**

1. Department of Surgery A, Heinrich Heine University and University Hospital Düsseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany. 2. Institute of Pathology, Heinrich Heine University and University Hospital Düsseldorf, Mooreenstrasse 5, 40225 Duesseldorf, Germany. 3. Coordination Centre for Clinical Trials, Heinrich Heine University and University Hospital Düsseldorf, Mooreenstrasse 5, 40225 Duesseldorf, Germany.

**Received:** 13 November 2012 **Accepted:** 2 August 2013

**Published:** 12 August 2013

**References**

1. Pitti RM, Mansters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271(22):12687–12690.

2. Wiley SR, Schooley K, Smolak PJ, Qin WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3(6):673–682.

3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Mansters SA, Blackie C, Chang L, McMuntry AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104(2):155–162.

4. Dejooez M, Rump U, Makotsa C, Krieg A, Walczak H, Gabbott HE, Gerhartz CD: Sensitivity to TRAIL/APO-2L mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 2000, 7(11):1127–1136.

5. Gura T: How TRAIL kills cancer cells, but not normal cells. Science 1997, 277(5327):768.

6. Sheridan JP, Mansters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood W, et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277(5327):818–821.

7. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Bolani N, Tirmour NS, Gerhart MJ, Schooley KA, Smith CA, et al: TRAIL-Δ: a novel apoptosis-mediating receptor for TRAIL. Embo J 1999, 18(7):1538–1537.

8. Walczak H, Miller RE, Anai K, Ginaki B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5(2):157–163.

9. Dimberg LV, Anderson CK, Camidge R, Behbahani K, Thorbum A, Ford HL: On the TRAIL to successful cancer therapy? Predicting and countering resistance against TRAIL-based therapeutics. Oncogene 2013, 32(11):1491–1500.

10. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG: The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death receptor signaling profile. J Biol Chem 2001, 276(16):13505–13512.

11. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG: TRAIL-R4, a new member of the emerging TRAIL receptor family. J Exp Med 1999, 186(7):1165–1170.

12. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dull E, Appelbaum ER, Eichman C, DiPrinzio R, et al: Osteoprotegerin is a receptor for the cytotopic ligand TRAIL. J Biol Chem 1998, 273(24):14563–14567.

13. MacFarlane M, Ahmad M, Srivastava SM, Fernandes-A trei R, Cohen TM, Alnemri ES: Identification and molecular cloning of two novel receptors for the cytotopic ligand TRAIL. J Biol Chem 1997, 272(41):25417–25420.

14. Mansters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, et al: A novel receptor for Apo2L/ TRAIL contains a truncated death domain. Curd Biol 1997, 7(12):1003–1006.

15. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277(5327):813–818.

16. Pan G, O’Rourke K, Chinnayyan AM, Gentz R, Eimer N, Ni J, Dixit VM: The receptor for the cytotopic ligand TRAIL. Science 1997, 276(5309):111–113.

17. Kischkel FC, Lawrence DA, Chuntharapa A, Schow P, Kim KJ, Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12(6):581–620.

18. Bodmer JL, Hailer N, Reynard S, Vinciguerra P, Schneider P, Joo P, Blenis J, Tschopp J: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000, 2(4):241–243.

19. Kuang AA, Diehl GE, Zhang J, Winoto A: FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000, 275(33):25065–25068.

20. Miyazaki T, Reed JC: Identification and characterization of two TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2001, 2(6):493–500.

21. Sprick MR, Weigand MA, Rieser E, Rauch CT, Joo P, Blenis J, Krammer PH, Walczak H: FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12(6):599–609.

22. Mongoliosapa Y, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI, Sreenan GP: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998, 160(3):1–6.

23. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L: Death receptor 5, a new member of the TNF family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7(6):821–830.

24. Schneider P, Thome M, Burns K, Bodmer J, Hofmann K, Kakka T, Hailer N, Tschopp J: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997, 7(6):831–846.

25. Hu WH, Johnson H, Shu HB: Tumor necrosis factor-related apoptosis-inducing ligand receptor signaling network and NF-kappaB activation and apoptosis through distinct pathways. J Biol Chem 1999, 274(33):20603–20610.

26. Secchiero P, Gorielli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zanli G: TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107(17):2250–2256.

27. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001, 276(19):16484–16490.
28. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I: TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22(25):3842–3852.

29. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorencov D, Emmo D, Rodier C, Kalthoff H, Wajant H: TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25(56):7434–7439.

30. Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, et al: The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Radiat Oncol Biol Phys 2009, 75(1):209–211.

31. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezem HM, de Jong S: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003, 9(9):3397–3405.

32. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, et al: Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010, 16(13):3442–3451.

33. Jiang ZH, Wu JY: Alternative splicing and programmed cell death. Proc Soc Exp Biol Med 1999, 220(2):64–72.

34. Schwerk C, Schulze-Osthoff K: Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005, 19(1):1–13.

35. Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, Fang B, Gabbert HE, Gerharz CD, Mahorka C: TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 2003, 88(6):918–927.

36. Krieg A, Schulte am Esch J 2nd, Ramp U, Hosch SB, Kneefel WT, Gabbert HE, Mahorka C: TRAIL-R4-beta: a new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1. Biochem Biophys Res Commun 2006, 349(1):115–121.

37. Koyama S, Koike N, Adachi S: Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J Cancer Res Clin Oncol 2002, 128(2):73–79.

38. Watanabe H, Jass JR, Sobin LH: Histological typing of oesophageal and gastric tumours, WHO International Classification of Tumours. 2nd edition. New York: Springer-Verlag; 1998.

39. Sobin LH, Wittekind C: TNM classification of malignant tumors. 5th edition. New York: Wiley-Liss; 1997.

40. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162(1):156–159.

41. Bennett MW, O’Connell J, O’Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998, 160(1):5669–5675.

42. Ryan AE, Lane S, Shanahan F, O’Connell J, Houston AM: Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinog 2006, 5:5.

43. Ryan KR, McCue D, Andersson SM: Fas-mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation. J Leukoc Biol 2005, 78(1):43–50.

doi:10.1186/1471-2407-13-384

Cite this article as: Krieg et al.: Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-y as a prognostic marker. BMC Cancer 2013 13:384.